Sixuan Chen, Liping Tu, Quanhua Chen
The field of spatial pharmacology has emerged as a critical framework for understanding the complex interactions between anti-cancer immunomodulators, tumor cells, and the tumor microenvironment (TME) at single-cell resolution.
The field of spatial pharmacology has emerged as a critical framework for understanding the complex interactions between anti-cancer immunomodulators, tumor cells, and the tumor microenvironment (TME) at single-cell resolution. This review synthesizes the theoretical foundations, historical evolution, clinical applications, diagnostic techniques, therapeutic strategies, and future directions of spatial pharmacology in cancer immunotherapy. By integrating single-cell analysis, signaling dynamics, and multimodal approaches, spatial pharmacology addresses the limitations of traditional "one-size-fits-all" therapies by accounting for intratumoral heterogeneity, drug target accessibility, and immune cell spatial organization. Key advancements include single-cell RNA sequencing (scRNA-seq) for mapping drug target pathway activation, imaging techniques for visualizing signaling dynamics, and multimodal diagnostics for personalized treatment design. Clinical applications range from optimizing combinatorial regimens in metastatic renal cell carcinoma to predicting immunotherapy response in triple-negative breast cancer. Despite challenges such as overcoming drug resistance and enhancing target accessibility, emerging technologies like spatial transcriptomics and artificial intelligence (AI)-driven multi-omics integration promise to revolutionize precision oncology. This review highlights how spatial pharmacology is transforming cancer immunotherapy by enabling tailored interventions that account for the spatial and temporal complexity of tumor-immune interactions.